| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share |
The following is a summary of awards outstanding as of June 30, 2026 and 2025, which are not included in the computation of basic and diluted weighted average shares:
|
|
|
|
|
|
|
|
|
|
|
Three and six months ended
June 30, |
|
|
|
2026 |
|
|
2025 |
|
Stock options (excluding exercisable penny stock options) |
|
|
9,883,389 |
|
|
|
8,831,326 |
|
Restricted stock units |
|
|
397,039 |
|
|
|
283,411 |
|
Warrants |
|
|
6,545,785 |
|
|
|
5,827,031 |
|
Performance restricted stock units |
|
|
2,800,000 |
|
|
|
— |
|
Total |
|
|
19,626,213 |
|
|
|
14,941,768 |
|
|
| Schedule of Segment Reporting Information, by Segment |
In addition to the significant expense categories included within the total net loss presented on the Company's Statements of Operations, the following table sets forth significant segment expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, |
|
|
Six months ended June 30, |
|
(in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Employee expenses |
|
$ |
3,385 |
|
|
$ |
2,833 |
|
|
$ |
6,247 |
|
|
$ |
5,872 |
|
Research and Development (excluding employee expenses): |
|
|
|
|
|
|
|
|
|
|
|
|
Consulting and professional fees |
|
|
405 |
|
|
|
452 |
|
|
|
872 |
|
|
|
868 |
|
Clinical study expenses |
|
|
173 |
|
|
|
7 |
|
|
|
259 |
|
|
|
11 |
|
Product development |
|
|
91 |
|
|
|
647 |
|
|
|
203 |
|
|
|
1,356 |
|
Other* |
|
|
298 |
|
|
|
335 |
|
|
|
588 |
|
|
|
638 |
|
Total Research and development expense |
|
$ |
967 |
|
|
$ |
1,441 |
|
|
$ |
1,922 |
|
|
$ |
2,873 |
|
Selling, general and administrative expense (excluding employee expenses): |
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses |
|
|
443 |
|
|
|
592 |
|
|
|
1,057 |
|
|
|
1,325 |
|
Commercialization readiness expenses |
|
|
297 |
|
|
|
171 |
|
|
|
582 |
|
|
|
468 |
|
Total Selling, general and administrative expense |
|
|
740 |
|
|
|
763 |
|
|
|
1,639 |
|
|
|
1,793 |
|
Total operating expenses |
|
$ |
5,092 |
|
|
$ |
5,037 |
|
|
$ |
9,808 |
|
|
$ |
10,538 |
|
* Other primarily includes patent, software, product testing and other miscellaneous expenses for the three and six months ended June 30, 2026 and 2025.
|